Atossa Therapeutics（纳斯达克代码：ATOS）近日披露了其2025财年第四季度及全年的财务数据，并同步更新了公司最新的运营进展。
在截至2025年12月31日的第四季度，公司在药物研发项目上取得了关键推进。其主要在研产品，针对乳腺癌的创新疗法，已进入重要的临床研究阶段。与此同时，公司财务状况保持稳健，为后续临床开发提供了有力支持。
回顾整个2025财年，Atossa Therapeutics在临床管线推进、公司治理以及知识产权布局方面均实现了既定目标。管理层表示，未来将继续专注于核心项目的开发，致力于为患者带来新的治疗选择，并为股东创造长期价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.